Novo candidato a remdio para emagrecimento da Eli Lilly acerto triplo Gigante farmacutica compartilhou resultados de estudo de Fase 3 avaliando a eficcia do retatrutide, um agonista triplo que atua em trs receptores metablicos, ao contrrio das geraes anteriores Enquanto Wall Street mantm ateno redobrada no portflio de medicamentos para perda de peso da Eli Lilly, a companhia divulgou resultados positivos para um novo candidato, que atingiu todos os desfechos primrios e secundrios importantes em um novo estudo.
Adults may generally qualify if they have a BMI of 30 or higher, which meets the medical definition of obesity, or a BMI of 27 or higher with at least one weight-related medical condition
Employers should cover all evidence-based obesity care options, including drugs, nutrition therapy, behavioral health services and surgery, the groups say
The convenience factor
Management of hyperglycemia in type 2 diabetes, 2022: a consensus report by the American Diabetes Association and the European Association for the Study of Diabetes
Presented for research literature review only Stromsdorfer KL et al
